532 related articles for article (PubMed ID: 15364796)
1. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
[TBL] [Abstract][Full Text] [Related]
2. Effect of pravastatin in people with diabetes and chronic kidney disease.
Tonelli M; Keech A; Shepherd J; Sacks F; Tonkin A; Packard C; Pfeffer M; Simes J; Isles C; Furberg C; West M; Craven T; Curhan G
J Am Soc Nephrol; 2005 Dec; 16(12):3748-54. PubMed ID: 16251235
[TBL] [Abstract][Full Text] [Related]
3. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease.
Tonelli M; Isles C; Craven T; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; West M; Packard C; Curhan GC
Circulation; 2005 Jul; 112(2):171-8. PubMed ID: 15998677
[TBL] [Abstract][Full Text] [Related]
4. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
Tokmakova MP; Skali H; Kenchaiah S; Braunwald E; Rouleau JL; Packer M; Chertow GM; Moyé LA; Pfeffer MA; Solomon SD
Circulation; 2004 Dec; 110(24):3667-73. PubMed ID: 15569840
[TBL] [Abstract][Full Text] [Related]
5. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS).
Ix JH; Mercado N; Shlipak MG; Lemos PA; Boersma E; Lindeboom W; O'Neill WW; Wijns W; Serruys PW
Am Heart J; 2005 Mar; 149(3):512-9. PubMed ID: 15864241
[TBL] [Abstract][Full Text] [Related]
6. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
7. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
8. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
[TBL] [Abstract][Full Text] [Related]
9. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
Go AS; Yang J; Ackerson LM; Lepper K; Robbins S; Massie BM; Shlipak MG
Circulation; 2006 Jun; 113(23):2713-23. PubMed ID: 16754803
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
11. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
12. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
Asselbergs FW; Diercks GF; Hillege HL; van Boven AJ; Janssen WM; Voors AA; de Zeeuw D; de Jong PE; van Veldhuisen DJ; van Gilst WH;
Circulation; 2004 Nov; 110(18):2809-16. PubMed ID: 15492322
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Best PJ; Steinhubl SR; Berger PB; Dasgupta A; Brennan DM; Szczech LA; Califf RM; Topol EJ;
Am Heart J; 2008 Apr; 155(4):687-93. PubMed ID: 18371477
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study.
Jardine AG; Fellström B; Logan JO; Cole E; Nyberg G; Grönhagen-Riska C; Madsen S; Neumayer HH; Maes B; Ambühl P; Olsson AG; Pedersen T; Holdaas H
Am J Kidney Dis; 2005 Sep; 46(3):529-36. PubMed ID: 16129216
[TBL] [Abstract][Full Text] [Related]
15. [Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].
Byington RP; Jukema JW; Salonen JT; Pitt B; Bruschke AV; Hoen H; Furberg CD; Mancini GB
Fortschr Med; 1996 Mar; 114(8):91-8. PubMed ID: 8647574
[TBL] [Abstract][Full Text] [Related]
16. Beta-blockers for coronary heart disease in chronic kidney disease.
Chonchol M; Benderly M; Goldbourt U
Nephrol Dial Transplant; 2008 Jul; 23(7):2274-9. PubMed ID: 18187497
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction.
Wattanakit K; Coresh J; Muntner P; Marsh J; Folsom AR
J Am Coll Cardiol; 2006 Sep; 48(6):1183-9. PubMed ID: 16979003
[TBL] [Abstract][Full Text] [Related]
18. Pravastatin and cardiovascular risk in moderate chronic kidney disease.
Nakamura H; Mizuno K; Ohashi Y; Yoshida T; Hirao K; Uchida Y;
Atherosclerosis; 2009 Oct; 206(2):512-7. PubMed ID: 19423108
[TBL] [Abstract][Full Text] [Related]
19. Detection and awareness of moderate to advanced CKD by primary care practitioners: a cross-sectional study from Italy.
Minutolo R; De Nicola L; Mazzaglia G; Postorino M; Cricelli C; Mantovani LG; Conte G; Cianciaruso B
Am J Kidney Dis; 2008 Sep; 52(3):444-53. PubMed ID: 18468747
[TBL] [Abstract][Full Text] [Related]
20. Renal dysfunction predicts long-term mortality in patients with lower extremity arterial disease.
Pasqualini L; Schillaci G; Pirro M; Vaudo G; Siepi D; Innocente S; Ciuffetti G; Mannarino E
J Intern Med; 2007 Dec; 262(6):668-77. PubMed ID: 17908164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
